Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

cubic pharmaceuticals ltd - granisetron hydrochloride - oral tablet - 2mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

colorama pharmaceuticals ltd - granisetron hydrochloride - oral tablet - 2mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

ennogen healthcare ltd - granisetron hydrochloride - oral tablet - 2mg

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

j m mcgill ltd - granisetron hydrochloride - oral tablet - 2mg

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - granisetron hydrochloride, quantity: 2.24 mg (equivalent: granisetron, qty 2 mg) - tablet, film coated - excipient ingredients: magnesium stearate; microcrystalline cellulose; lactose monohydrate; sodium starch glycollate; hypromellose; titanium dioxide; polysorbate 80; macrogol 400 - adults: kytril (tablets and injection) is indicated for use in adults for: the prevention of nausea and vomiting induced by cytotoxic chemotherapy; the prevention of nausea and vomiting induced by radiotherapy.

Storbritannien - engelsk - MHRA (Medicines & Healthcare Products Regulatory Agency)

torrent pharma (uk) ltd - granisetron hydrochloride - oral tablet - 1mg

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 1.09 mg (equivalent: topotecan, qty 1 mg) - injection, concentrated - excipient ingredients: tartaric acid; hydrochloric acid; sodium hydroxide; water for injections - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

accord healthcare pty ltd - topotecan hydrochloride, quantity: 4.346 mg (equivalent: topotecan, qty 4 mg) - injection, concentrated - excipient ingredients: hydrochloric acid; sodium hydroxide; water for injections; tartaric acid - topotecan accord is indicated as single agent therapy for the treatment of patients with:,? small cell lung carcinoma after failure of first line chemotherapy.,? metastatic carcinoma of the ovary after failure of first-line or subsequent therapy.,topotecan accord is indicated in combination with cisplatin for the treatment of patients with:,? histologically confirmed stage iv-b, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.

Canada - engelsk - Health Canada

jamp pharma corporation - granisetron (granisetron hydrochloride) - tablet - 1mg - granisetron (granisetron hydrochloride) 1mg - 5-ht3 receptor antagonists

Irland - engelsk - HPRA (Health Products Regulatory Authority)

b. braun melsungen ag - granisetron hydrochloride granisetron - solution for injection - 1 mg/ml